Portal:IEM/CoveredPathways

From WikiPathways

(Difference between revisions)
Jump to: navigation, search
Line 3: Line 3:
|-
|-
| 13 || Disorders of pyrimidine and purine metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4225 WP4225] and [https://www.wikipathways.org/index.php/Pathway:WP4224 WP4224] || 41 || style="font-style: italic; color: blue;" | Approved
| 13 || Disorders of pyrimidine and purine metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4225 WP4225] and [https://www.wikipathways.org/index.php/Pathway:WP4224 WP4224] || 41 || style="font-style: italic; color: blue;" | Approved
 +
|-
 +
| 15 || Creatine disorders || [https://www.wikipathways.org/index.php/Pathway:WP5190 WP5190] || 32 || style="font-style: italic; color: blue;" | Approved
|-
|-
| 16 || Disorders of glutathione metabolism || style="font-style: italic; color: red;" | [https://www.wikipathways.org/index.php/Pathway:WP4518 WP4518]  || 42 || style="font-style: italic; color: blue;" | Approved
| 16 || Disorders of glutathione metabolism || style="font-style: italic; color: red;" | [https://www.wikipathways.org/index.php/Pathway:WP4518 WP4518]  || 42 || style="font-style: italic; color: blue;" | Approved
Line 38: Line 40:
| 35 || Disorders of molybdenum metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4507 WP4507] and [https://www.wikipathways.org/index.php/Pathway:WP4504 WP4504] || 12|| style="font-style: italic; color: blue;" | Approved
| 35 || Disorders of molybdenum metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4507 WP4507] and [https://www.wikipathways.org/index.php/Pathway:WP4504 WP4504] || 12|| style="font-style: italic; color: blue;" | Approved
|-
|-
-
| 42 || Disorders of pyruvate and Krebs cycle metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4236 WP4236] || 20|| style="font-style: italic; color: blue;" | Approved
+
| 36 || Disorders of copper , zinc and selenium metabolism|| [https://www.wikipathways.org/index.php/Pathway:WP5189 WP5189] || 39 || style="font-style: italic; color: blue;" | Approved
|-
|-
-
| 47 || Primary CoQ10 deficiencies || [https://www.wikipathways.org/index.php/Pathway:WP5037 WP5037] || 16|| style="font-style: italic; color: blue;" | Approved
+
| 37 || Iron metabolism disorder || [https://www.wikipathways.org/index.php/Pathway:WP5172 WP5172] || 40 || style="font-style: italic; color: blue;" | Approved
|-
|-
-
| 53 || Disorders of lipoprotein metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4522 WP4522] || 43|| style="font-style: italic; color: blue;" | Approved
+
| 39 || Disorders of carbohydrate and glucose transport || Fig.18.3:[https://www.wikipathways.org/index.php/Pathway:WP5173 WP5173],  <br/> Fig.18.4: [https://www.wikipathways.org/index.php/Pathway:WP5178 WP5178]   || 18 || style="font-style: italic; color: blue;" | Approved
|-
|-
-
| 55 || Disorders of steroid metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4523 WP4523] and [https://www.wikipathways.org/index.php/Pathway:WP4524 WP4524] || 37|| style="font-style: italic; color: blue;" | Approved
+
| 42 || Disorders of pyruvate and Krebs cycle metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4236 WP4236] || 20|| style="font-style: italic; color: blue;" | Approved
|-
|-
-
| 60 || Lysosomal storage disorders || [https://www.wikipathways.org/index.php/Pathway:WP4153 WP4153] || 25|| style="font-style: italic; color: blue;" | Approved
+
| 47 || Primary CoQ10 deficiencies || [https://www.wikipathways.org/index.php/Pathway:WP5037 WP5037] || 16|| style="font-style: italic; color: blue;" | Approved
|-
|-
-
| 66 || Congenital disorders of N-linked and O-linked glycosylation || [https://www.wikipathways.org/index.php/Pathway:WP4521 WP4521] || 30|| style="font-style: italic; color: blue;" | Approved
+
| 48 || Disorders of carnitine, fatty acid and fatty aldehyde metabolism || [https://www.wikipathways.org/index.php/Pathway:WP5123 WP5123] || 17 || style="font-style: italic; color: orange;" | In Progress
|-
|-
-
| 69 || Cerebral organic acidurias || [https://www.wikipathways.org/index.php/Pathway:WP4519 WP4519] and [https://www.wikipathways.org/index.php/Pathway:WP5030 WP5030] || 8 & 9|| style="font-style: italic; color: blue;" | Approved
+
| 50 || Disorders of ketone body metabolism || Fig.23.1 and 23.2:[https://www.wikipathways.org/index.php/Pathway:WP5175 WP5175],  <br/> Fig.23.3: [https://www.wikipathways.org/index.php/Pathway:WP5195 WP5195] || 23|| style="font-style: italic; color: blue;" | Approved
|-
|-
-
| ? || Disorders of phosphoinositide metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4971 WP4971] || ? || style="font-style: italic; color: blue;" | Approved
+
| 52 || Disorders of eicosanoid metabolism (including leukotrienes) || [https://www.wikipathways.org/index.php/Pathway:WP5171 WP5171] || 38|| style="font-style: italic; color: blue;" | Approved
|-
|-
-
| ? || Oxysterols derived from cholesterol || [https://www.wikipathways.org/index.php/Pathway:WP4545 WP4545] || ? || style="font-style: italic; color: blue;" | Approved
+
| 53 || Disorders of lipoprotein metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4522 WP4522] || 43|| style="font-style: italic; color: blue;" | Approved
|-
|-
-
 
+
| 54 || Cholesterol synthesis disorders || [https://www.wikipathways.org/index.php/Pathway:WP5193 WP5193] || 36 || style="font-style: italic; color: blue;" | Approved
-
| 52 || Disorders of eicosanoid metabolism (including leukotrienes) || [https://www.wikipathways.org/index.php/Pathway:WP5171 WP5171] || 38|| style="font-style: italic; color: blue;" | Approved
+
|-
 +
| 55 || Disorders of steroid metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4523 WP4523] and [https://www.wikipathways.org/index.php/Pathway:WP4524 WP4524] || 37|| style="font-style: italic; color: blue;" | Approved
|-
|-
| 56 || Disorders of Bile acid synthesis (and biliary transport) || [https://www.wikipathways.org/index.php/Pathway:WP5176 WP5176] || 34 || style="font-style: italic; color: blue;" | Approved
| 56 || Disorders of Bile acid synthesis (and biliary transport) || [https://www.wikipathways.org/index.php/Pathway:WP5176 WP5176] || 34 || style="font-style: italic; color: blue;" | Approved
-
|-
 
-
| 15 || Creatine disorders || [https://www.wikipathways.org/index.php/Pathway:WP5190 WP5190] || 32 || style="font-style: italic; color: blue;" | Approved
 
|-
|-
| 57 || Disorders of Heme metabolism || [https://www.wikipathways.org/index.php/Pathway:WP5169 WP5169] || 33 || style="font-style: italic; color: blue;" | Approved
| 57 || Disorders of Heme metabolism || [https://www.wikipathways.org/index.php/Pathway:WP5169 WP5169] || 33 || style="font-style: italic; color: blue;" | Approved
|-
|-
-
| 54 || Cholesterol synthesis disorders || [https://www.wikipathways.org/index.php/Pathway:WP5193 WP5193] || 36 || style="font-style: italic; color: blue;" | Approved
+
| 60 || Lysosomal storage disorders || [https://www.wikipathways.org/index.php/Pathway:WP4153 WP4153] || 25|| style="font-style: italic; color: blue;" | Approved
|-
|-
-
 
+
| 65 || Disorders of oxalate metabolism || [https://www.wikipathways.org/index.php/Pathway:WP5166 WP5166] || 28 || style="font-style: italic; color: blue;" | Approved
-
| 50 || Disorders of ketone body metabolism || Fig.23.1 and 23.2:[https://www.wikipathways.org/index.php/Pathway:WP5175 WP5175],  <br/> Fig.23.3: [https://www.wikipathways.org/index.php/Pathway:WP5195 WP5195] || 23|| style="font-style: italic; color: blue;" | Approved
+
|-
|-
-
| 39 || Disorders of carbohydrate and glucose transport || Fig.18.3:[https://www.wikipathways.org/index.php/Pathway:WP5173 WP5173],  <br/> Fig.18.4: [https://www.wikipathways.org/index.php/Pathway:WP5178 WP5178]   || 18 || style="font-style: italic; color: blue;" | Approved
+
| 66 || Congenital disorders of N-linked and O-linked glycosylation || [https://www.wikipathways.org/index.php/Pathway:WP4521 WP4521] || 30|| style="font-style: italic; color: blue;" | Approved
|-
|-
-
| ? || Mitochondrial oxidative phosphorylation || || 22 || style="font-style: italic; color: orange;" | In Progress
+
| 69 || Cerebral organic acidurias || [https://www.wikipathways.org/index.php/Pathway:WP4519 WP4519] and [https://www.wikipathways.org/index.php/Pathway:WP5030 WP5030] || 8 & 9|| style="font-style: italic; color: blue;" | Approved
|-
|-
-
| 37 || Iron metabolism disorder || [https://www.wikipathways.org/index.php/Pathway:WP5172 WP5172] || 40 || style="font-style: italic; color: blue;" | Approved
+
| - || Disorders of phosphoinositide metabolism || [https://www.wikipathways.org/index.php/Pathway:WP4971 WP4971] || NA || style="font-style: italic; color: blue;" | Approved
|-
|-
-
 
+
| - || Oxysterols derived from cholesterol || [https://www.wikipathways.org/index.php/Pathway:WP4545 WP4545] || NA || style="font-style: italic; color: blue;" | Approved
-
| 48 || Disorders of carnitine, fatty acid and fatty aldehyde metabolism || [https://www.wikipathways.org/index.php/Pathway:WP5123 WP5123] || 17 || style="font-style: italic; color: orange;" | In Progress
+
|-
|-
-
 
+
| - || Mitochondrial oxidative phosphorylation || || 22 || style="font-style: italic; color: orange;" | In Progress
-
| 65 || Disorders of oxalate metabolism || [https://www.wikipathways.org/index.php/Pathway:WP5166 WP5166] || 28 || style="font-style: italic; color: blue;" | Approved
+
-
|-
+
-
 
+
-
| 36 || Disorders of copper , zinc and selenium metabolism|| [https://www.wikipathways.org/index.php/Pathway:WP5189 WP5189] || 39 || style="font-style: italic; color: blue;" | Approved
+
|-
|-
-
 
-
 
|}
|}

Revision as of 13:06, 13 April 2022

Chapter ed. 5 Title Links WP Chapter ed. 4 Status Diseases: x from ch. ed. 4
(+y) from other ch.
13 Disorders of pyrimidine and purine metabolism WP4225 and WP4224 41 Approved
15 Creatine disorders WP5190 32 Approved
16 Disorders of glutathione metabolism WP4518 42 Approved
17 Disorders of ammonia detoxification WP4595 4 Approved
18 Disorders of amino acid transport WP5029 6 In Progress
19 Disorders of monoamine metabolism WP4220 31 Approved
20 Disorders of phenylalanine and tetrahydrobiopterin metabolism WP4156 1 Approved 7 (+3), non missing
21 Disorders of tyrosine metabolism WP4506 2 Approved 5, non missing
22 Disorders of sulfur amino acid and sulfide metabolism WP4292 3 Approved 7, non missing
23 Disorders of branched-chain amino acid metabolism WP4686 7 In Progress
26 Disorders of glycine metabolism Fig.5.1:WP5028,
Fig.5.4: WP5026 		5 In Progress
26 Disorders of glycine metabolism Fig.5.2: WP4688
Fig.5.3: WP4157, 		5 Approved
28 Disorders of cobalamin metabolism WP4271 13 Approved
29 Disorders of folate metabolism WP4259 and WP4288 10 Approved
30 Disorders of biotin metabolism WP5031 14 Approved
31 Disorders of thiamine metabolism WP4297 15 Approved
32 Disorders of riboflavin metabolism WP5037 16 Approved
34 Vitamin B6 -Dependent and Responsive Disorders WP4228 11 Approved
35 Disorders of molybdenum metabolism WP4507 and WP4504 12 Approved
36 Disorders of copper , zinc and selenium metabolism WP5189 39 Approved
37 Iron metabolism disorder WP5172 40 Approved
39 Disorders of carbohydrate and glucose transport Fig.18.3:WP5173,
Fig.18.4: WP5178 		18 Approved
42 Disorders of pyruvate and Krebs cycle metabolism WP4236 20 Approved
47 Primary CoQ10 deficiencies WP5037 16 Approved
48 Disorders of carnitine, fatty acid and fatty aldehyde metabolism WP5123 17 In Progress
50 Disorders of ketone body metabolism Fig.23.1 and 23.2:WP5175,
Fig.23.3: WP5195 		23 Approved
52 Disorders of eicosanoid metabolism (including leukotrienes) WP5171 38 Approved
53 Disorders of lipoprotein metabolism WP4522 43 Approved
54 Cholesterol synthesis disorders WP5193 36 Approved
55 Disorders of steroid metabolism WP4523 and WP4524 37 Approved
56 Disorders of Bile acid synthesis (and biliary transport) WP5176 34 Approved
57 Disorders of Heme metabolism WP5169 33 Approved
60 Lysosomal storage disorders WP4153 25 Approved
65 Disorders of oxalate metabolism WP5166 28 Approved
66 Congenital disorders of N-linked and O-linked glycosylation WP4521 30 Approved
69 Cerebral organic acidurias WP4519 and WP5030 8 & 9 Approved
- Disorders of phosphoinositide metabolism WP4971 NA Approved
- Oxysterols derived from cholesterol WP4545 NA Approved
- Mitochondrial oxidative phosphorylation 22 In Progress


Information on Pathway Curation:

This Table provides an overview of which chapters have been covered by WikiPathways. Approved pathways are coloured blue; pathways which still need work (however are a part of the database) are coloured orange.


Tip:

Click on the arrows behind the Table headers to sort this table based on Chapter number (edition 4 and 5 available), title, WikiPathways reference and Curation Status.


Pathway Visualisations

View all digitized Pathways from the Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases by Blau et al. (see it on Scholia.)


How to add a pathway to the portal

The list of Featured Pathways is not static and can be updated at any time. If you know of a pathway that should be added, please contact Denise Slenter.

Retrieved from "https://classic.wikipathways.org/index.php/Portal:IEM/CoveredPathways"
Personal tools